This paper evaluates the concept and evidence base for early biologic intervention in asthma with the goal of achieving disease remission, examining whether current data support this as a viable strategy.
The paper appears to be a commentary or review rather than a primary trial, so no original efficacy or safety data are reported; conclusions are likely based on existing literature synthesis.
Early biologic use for asthma remission is an emerging concept, but clinicians should interpret current evidence cautiously until robust trial data confirm long-term remission outcomes.
Explore related topics
